Overall, we herein propose a new tumor-suppressor function of ATGL in HCC, which might be exploited for creating personalized therapies, possibly in combination with existing therapeutic regimens, aimed at selectively kill cancer cells. The gene discussed is PNPLA2; the disease is hepatocellular carcinoma.